

Dietary calcium impairs tomato lycopene bioavailability in healthy humans

Patrick Borel, C Desmarchelier, U Dumont, C Halimi, D L Lairon, D Page, C

L Sébédio, C Buisson, C Buffière, Didier Remond

▶ To cite this version:

Patrick Borel, C Desmarchelier, U Dumont, C Halimi, D L Lairon, et al.. Dietary calcium impairs tomato lycopene bioavailability in healthy humans. British Journal of Nutrition, 2016, 116 (12), pp.2091 - 2096. 10.1017/s0007114516004335 . hal-01478884

HAL Id: hal-01478884 https://amu.hal.science/hal-01478884

Submitted on 28 Feb 2017 $\,$

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Dietary calcium impairs tomato lycopene bioavailability in healthy humans

Patrick Borel¹*†, C. Desmarchelier¹†, U. Dumont¹, C. Halimi¹, D. Lairon¹, D. Page², J. L. Sébédio³, C. Buisson³, C. Buffière³ and D. Rémond³

¹NORT Nutrition, Obesity and Risk of Thrombotis, Aix-Marseille University, INRA National Institute for Agricultural Research, INSERM National Institute of Health and Medical Research, 13005 Marseille, France ²Security and quality of plant products (SQPOV), INRA, Université d'Avignon et des Pays du Vaucluse, 84140 Avignon, France ³Human Nutrition Unit (UNH), INRA, Université d'Auvergne, 63000 Clermont-Ferrand, France

(Submitted 11 April 16 - Final revision received 24 November 2016 - Accepted 29 November 2016)

Abstract

Lycopene (LYC) bioavailability is relatively low and highly variable, because of the influence of several factors. Recent *in vitro* data have suggested that dietary Ca can impair LYC micellarisation, but there is no evidence whether this can lead to decreased LYC absorption efficiency in humans. Our objective was to assess whether a nutritional dose of Ca impairs dietary LYC bioavailability and to study the mechanism(s) involved. First, in a randomised, two-way cross-over study, ten healthy adults consumed either a test meal that provided 19-mg (all-E)-LYC from tomato paste or the same meal plus 500-mg calcium carbonate as a supplement. Plasma LYC concentration was measured at regular time intervals over 7 h postprandially. In a second approach, an *in vitro* digestion model was used to assess the effect of increasing Ca doses on LYC micellarisation and on the size and zeta potential of the mixed micelles produced during digestion of a complex food matrix. LYC bioavailability was diminished by 83% following the addition of Ca in the test meal. *In vitro*, Ca affected neither LYC micellarisation nor mixed micelle size but it decreased the absolute value of their charge by 39%. In conclusion, a nutritional dose of Ca can impair dietary LYC bioavailability in healthy humans. This inhibition could be due to the fact that Ca diminishes the electrical charge of micelles. These results call for a thorough assessment of the effects of Ca, or other divalent minerals, on the bioavailability of other carotenoids and lipophilic micronutrients.

Keywords: Carotenoids: Lycopene Absorption: Micelles: Bioaccessibility: Carotenoid micellarisation: Zeta potential

Lycopene (LYC) is a carotenoid pigment that gives tomatoes and tomato products their red colour. Both its dietary intake and blood concentration have been negatively associated with prostate cancer⁽¹⁻⁶⁾ and CVD⁽⁷⁻⁹⁾ risk.

LYC is very hydrophobic but paradoxically also poorly soluble in fat. This explains, at least in part, its low bioavailability, which has been estimated at about 23% when pure LYC was mixed with olive oil⁽¹⁰⁾ and at about 5% when it was ingested from tomato juice⁽¹¹⁾. LYC absorption efficiency is also highly variable because it is affected by numerous factors⁽¹²⁾. These factors can be either dietary, for example, the effect of the food matrix in which LYC is absorbed^(13,14), or linked to the physiological/genetic characteristics of the individual, for example, genetic polymorphisms that are involved in inter-individual variability in LYC bioavailability⁽¹⁵⁾.

LYC absorption is assumed to be closely related to that of dietary fat. After its extraction from the food matrix, LYC gets transferred to dietary fat⁽¹⁶⁾ and then to mixed micelles⁽¹⁷⁾. These particles carry LYC to the enterocyte where it is taken up via scavenger receptor class B type I (SR-BI)⁽¹⁸⁾ or perhaps via

other apical membrane proteins^(19,20). The fraction of LYC incorporated into mixed micelles during digestion is very low – that is, between 0.1 and about $2.7 \%^{(13,21)}$ – and is affected by numerous factors⁽¹²⁾ including the presence of other nutrients, for example, fat, fibres and minerals. As species of fatty acids present in mixed micelles can affect carotenoid micellarisation⁽²²⁾, also known as bioaccessibility, it has been hypothesised that Ca, which can lead to insoluble fatty acidsoap complex formation⁽²³⁾, could impair carotenoid micellarisation. This hypothesis is supported by a recent in vitro study that has shown that LYC micellarisation was diminished in the presence of Ca⁽²⁴⁾. As LYC micellarisation is assumed to be a key step for LYC bioavailability, the authors have suggested that if a similar interaction occurs in vivo - that is, in the human intestinal lumen - this can lead to diminished LYC absorption efficiency.

The objectives of this study were therefore to assess whether a nutritional dose of Ca can impair LYC bioavailability in healthy humans and, if so, to study the mechanism(s) involved.

Abbreviations: LYC, lycopene; SR-BI, scavenger receptor class B type I.

^{*} Corresponding author: P. Borel, email Patrick.Borel@univ-amu.fr

[†] P. Borel and C. Desmarchelier are joint first authors.

)

2

Methods

Subject number and characteristics

In all, ten healthy, non-obese subjects (five males, five females) were recruited for the study. As this was the first study dedicated to assess the effect of Ca on LYC bioavailability in humans, it was not possible to perform a statistical power analysis to calculate the number of subjects required to observe a significant effect. Thus, the number of subjects was chosen on the basis of the team's knowledge on the variability of the postprandial LYC plasma response^(14,15,25,26), and on the hypothesis that a very significant effect can be expected because in vitro studies have shown that Ca is able to strongly impair LYC bioaccessibility⁽²⁴⁾. Subjects had no history of chronic disease, hypocalcaemia, hyperlipidaemia or hyperglycaemia and were not taking any medication known to affect LYC or lipid metabolism (e.g. tetrahydrolipstatin, ezetimibe, phytosterols, cholestyramine, fibrates) the month before the study or during the study period. The present study was approved by the local Ethical Review Board (Comité de Protection des Personnes Sud-Est VI, approved study no. 2013-A00096-39). Procedures followed were in accordance with the Declaration of Helsinki of 1975 as revised in 1983. Objectives and requirements of the study were fully explained to all participants before starting the study, and written informed consent was obtained from each subject. Subject baseline characteristics are reported in Table 1.

Postprandial experiments

In order to assess the effect of Ca on LYC bioavailability, we measured the postprandial plasma LYC response to two LYC-rich test meals, separated by at least 3 weeks, and which contained either no supplement or a supplement that provided 500 mg Ca as calcium carbonate (Cacit 500[®]; Warner Chilcott). This dose of Ca is about half the RDA for a healthy male adult⁽²⁷⁾. Subjects were asked to refrain from the consumption of LYC supplements and LYC-rich foods 48 h before the postprandial experiments (an exclusion list was provided by a dietitian). In addition, subjects were asked to eat dinner between 19.00 and 20.00 hours the day before the postprandial experiments, and to then abstain from any food or beverage consumption with the exception of water. After the overnight fast, subjects arrived at the local Centre for Human Nutrition (Laboratory of Human Nutrition). A fasting blood sample was collected 20 min before administration of the meal. The subjects then consumed the test meal with or without the Ca supplement. The test meal provided 19 (SEM 1.3) mg (all-E)-LYC in 40-g tomato paste. The tomato paste (triple concentrated, refractive index 30.8° Brix), which came from the same barrel, was prepared using a cold-break process by Conserve de France S.A. The meal also contained 90-g cooked pork meat, 80-g pasta (dry weight; Lustucru® torti), 10-g olive oil and 250-ml mineral water (Volvic, which provided about 2.5-mg Ca and in which the effervescent supplement of calcium carbonate was mixed). Subjects were asked to consume the meal at a steady pace, with one half of the meal consumed in about 7-8 min and the remainder of the meal consumed within 15 min (to diminish the variability due to different rates of intake, and thus

gastric emptying). No other food or water was permitted over the following 7 h. Blood samples were collected at 20, 40, 60, 90, 120, 180, 240, 300, 360 and 420 min after meal consumption via evacuated purple-top glass tubes containing lithium heparin (BD Vacutainer[®]; Becton, Dickinson and Company). Tubes were immediately placed on ice and covered with aluminium foil to avoid light exposure. Plasma was isolated by centrifugation (10 min at 4°C and 2000 **g**) <2 h after collection and stored at -80°C until analysis.

In vitro digestion experiments

Corte-Real et al.⁽²⁴⁾ have recently reminded us that in the intestinal lumen Ca ions can be complexed by other molecules such as phosphate from animal products or phytic acid/oxalic acid from plant matrices. This complexation could attenuate the effect of Ca on several processes including its hypothesised impact on LYC micellarisation. We therefore used an in vitro digestion model that contained both an animal product and a plant matrix, meat and potato, respectively, in addition to a vegetable oil, olive $oil^{(13,22)}$. We also used the same source of LYC as was used in the clinical study, that is, tomato paste. The amounts of added Ca ranged between 10 and 80 mg/meal. which were equivalent to concentrations between 175 and 1400 mg/l. Note that the ratio mg Ca:g tomato paste in the meal used in the clinical study was 12.5, which amounted to 50 mg added Ca in the *in vitro* digestion test meal, as it contained 4 g of tomato paste. The in vitro digestion experiments were adapted from Reboul et al.⁽¹³⁾ with minor modifications⁽²²⁾. After the digestion experiments, the aqueous fractions, which contained the mixed micelles, were separated from oil droplets and food particles by centrifugation (2200 g for 1 h at 10°C). They were then collected and passed through a 0.8- and a 0.22-µm filter (Millipore) in order to discard the remaining small food particles and to obtain clear solutions. Aliquots of these solutions, which contained LYC in mixed micelles, were stored at -80°C until LYC analysis.

Lycopene extraction and analysis

Tomato paste LYC extraction and analysis were carried out as described by Page et al.⁽²⁸⁾. LYC in plasma and in samples from the in vitro experiments was extracted and analysed as described by Gleize et al.⁽²⁹⁾. In brief, up to 2 ml of the samples was de-proteinated by adding 1 volume of ethanol, which also contained echinenone as an internal standard. After adding 2 volumes of hexane, the mixture was vortexed for 10 min and centrifuged at 1200 $m{g}$ for 10 min at 4°C. The upper phase (containing LYC and echinenone) was collected, and the sample was extracted a second time with hexane following the same procedure. The hexane phases were pooled and evaporated to dryness under N gas. All extractions were performed at room temperature under dimmed light to minimise lightinduced damage. The dried residue was dissolved in 200 µl of methanol-dichloromethane (65:35, v/v). A volume of 150 µl was used for HPLC analysis.

The HPLC system comprised a Dionex separation module (P680 HPLC Pumps and ASI-100 Autosampler; Dionex) and a

UVD340U Dionex photodiode array detector (detection at 472 nm, spectral analysis between 300 and 600 nm). LYC and echinenone were separated using a 10×4.0 -mm, 5-µm C30 guard column (Chromoptic) followed by a 250×4.6 -mm internal diameter, 5-µm particle size, YMC C30 column (Chromoptic) held at 35°C. The mobile phase was composed of methanol, methyl tert-butyl ether and water. A flow rate of 1 ml/min was used. All-E-LYC and *cis*-LYC isomers were integrated together to obtain the sum of all LYC isomers. Quantification was performed using Chromeleon software (version 6.80 DU 13a; Dionex) comparing peak area with standard (all-E-LYC and echinenone) reference curves. All solvents used were of HPLC grade (Carlo Erba).

Measurement of mixed micelles size and zeta potential

The intensity-weighted mean hydrodynamic radius and the zeta potential of the mixed micelles were determined by photon correlation spectroscopy at 25°C (Zetasizer Nano ZS; Malvern Instruments), directly following their isolation after the *in vitro* digestions.

Calculation and statistical analysis

The trapezoidal approximation method was used to calculate the AUC of the postprandial plasma LYC concentration over 7 h. Micellarisation was defined as the percentage of LYC recovered in the micellar phase after *in vitro* digestion, in relation to the amount of LYC recovered in the digestive medium just before addition of artificial saliva.

Data are expressed as mean values with their standard errors. Means were compared by non-parametric tests, either the Mann–Whitney *U* test or the Wilcoxon signed-rank test when two groups, respectively, unpaired and paired, were compared. When more than two groups were compared, the Kruskal– Wallis test followed by Dunn's test as a *post boc* test was used. Statistical dependence between two variables was assessed by Spearman's rank-correlation coefficient. For all tests, the bilateral alpha risk was $\alpha = 0.05$. Statistical analyses were performed using Statview and SAS softwares (SAS Institute).

Results

Lycopene and calcium status of the subjects

Baseline characteristics of the subjects are shown in Table 1. The fasting plasma LYC concentration of the subjects was in the

 Table 1. Characteristics of the subjects*

 (Mean values with their standard errors)

Parameters	Mean	SEM
Age (years)	23.0	0.0
BMI (kg/m ²)	22.5	0.6
Glucose (mmol/l)†	4.24	0.17
TAG (mmol/l)†	0.88	0.12
Total cholesterol (mmol/l)†	4.86	0.21
Ionised Ca (mmol/l)†	1.21	0.01
Lycopene (nmol/l)†	461.10	146-31

* n 10 (five males, five females), all Caucasians.

† Fasting plasma variables.

range of values previously reported for healthy, French subjects^(15,30,31).

Effect of dietary calcium on lycopene bioavailability

The mean postprandial plasma LYC concentrations measured after consumption of the control and Ca test meals are shown in Fig. 1(a). It is noteworthy that the plasma LYC concentration increased 2 h after intake of the control meal, whereas it did not significantly increase until 5 h after intake of the Ca meal. In addition, the postprandial plasma LYC response, as evaluated by the AUC of the 0–7-h plasma LYC concentration, was significantly lower following consumption of the test meal with added Ca than following consumption of the test meal without added Ca (-83%, P=0.047) (Fig. 1(b)), and nine out of the ten subjects exhibited a decrease in their response (Fig. 1(c)).

Effect of calcium on tomato paste lycopene micellarisation during in vitro digestions

The micellarisation of LYC in the *in vitro* digestion experiment without added Ca was very low, about 0.6% of the amount present in the tomato paste. Furthermore, it was not significantly affected by the addition of Ca, up to 1400 mg/l, in the *in vitro* test meal (P=0.262, Kruskal–Wallis test; data not shown).

Effect of calcium on the size and zeta potential of particles produced during in vitro digestions

It should first be noted that only particles whose size corresponded to that of mixed micelles, that is, mean hydrodynamic diameter <10 nm, were observed in the micellar phase. The effect of Ca concentration on the size and zeta potential of the mixed micelles produced during the in vitro digestions is shown in Fig. 2. The mean diameter of the mixed micelles was positively, although non-significantly, correlated to Ca concentration ($\rho = 0.90$, P = 0.072). Nevertheless, there was no significant effect of Ca concentration on micelle size (P=0.162, Kruskal-Wallis test) (Fig. 2(a)). The zeta potential of the mixed micelles recovered after digestion of the control meal was negative, about -12 mV, and its absolute value was significantly diminished (P=0.049, Kruskal-Wallis test), down to about -5 mV, when Ca was added in the digestive medium (Fig. 2(b)). Nevertheless, there was no dose effect of the concentration of Ca on the zeta potential of mixed micelles.

Discussion

This study was initiated following a recent study that showed that Ca diminishes LYC micellarisation *in vitro*⁽²⁴⁾, suggesting that it could diminish LYC bioavailability. As both LYC status and LYC intake have been negatively associated with prostate cancer risk^(3,4,32), this interaction could partly explain the positive association observed between Ca intake and prostate cancer risk^(33,34), although this association is still under debate⁽³⁵⁾.

Our first objective was therefore to perform a clinical study dedicated to assess whether a dietary dose of Ca can



4



Fig. 1. Postprandial plasma lycopene (LYC) responses to a LYC-rich meal that contained either no added calcium or a calcium supplement. (a) Baselineadjusted plasma LYC concentration over 7 h after consumption of the LYC-rich meals (control meal (\square): meal without added calcium, meal plus calcium (\blacksquare): meal with 500 mg calcium carbonate). For each subject, postprandial plasma LYC concentrations were baseline adjusted by using the fasting plasma LYC concentration. (b) Mean AUC of the postprandial plasma LYC responses obtained after intake of either the control or the calcium-supplemented meal. Means were compared by Wilcoxon's signed-rank test. (c) Individual AUC of the postprandial plasma LYC responses (0–7 h AUC) after the control meal and after the meal that contained the calcium supplement.

significantly affect LYC bioavailability in healthy subjects. The results obtained showed that adding 500 mg Ca to a meal that contained a food source of LYC significantly impaired



Fig. 2. Effect of calcium concentration on physico-chemical parameters of mixed micelles produced during *in vitro* digestions. (a) Mixed micelle size. (b) Mixed micelle zeta potential. These two parameters were measured by photon correlation spectroscopy at 25°C. Means were compared by the Kruskal–Wallis test followed by Dunn's test as a *post hoc* test when the Kruskal–Wallis test was significant.

its bioavailability. This is the first time that such an effect is described, and this led us to perform *in vitro* studies to identify the mechanism(s) involved.

The first suspected mechanism was an inhibition of carotenoid micellarisation, as this was described by Bohn's group^(24,36). However, we did not observe this effect in our experiments. This apparent discrepancy could be due to the fact that we used a test meal where LYC, together with other nutrients, was brought by foods⁽¹³⁾ that contain molecules that can bind Ca, for example, phosphates in meat and oxalic acid in tomato paste, whereas Bohn's group used purified LYC incorporated in rapeseed oil without adding any food in their test meals. Yet, as suggested by Corte-Real et al.⁽²⁴⁾, foods contain chemicals that can bind Ca, leading to partial or even total masking of its inhibitory effect on LYC micellarisation. Of note, we verified the adequacy of our methods to detect a change in LYC micellarisation by measuring LYC bioaccessibility when only purified LYC incorporated in colza oil (i.e. no other food item) was present in our in vitro digestion model. We indeed observed a significant 84.7% decrease (P=0.006; data not shown) in LYC bioaccessibility when Ca (1000 mg/l) was added to the model. Thus, differences between the in vitro digestion protocols used (e.g. presence of an oral phase, no sonication before digestion, shorter gastric and duodenal phases with slightly different pH in our model) could also partly explain the differences between our results and the results obtained by Bohn's group. Nevertheless, an inhibitory effect of Ca on LYC micellarisation could occur at higher Ca concentrations, depending on the Ca-binding ability of foods co-ingested with the food source of LYC.

5

We also studied the effect of Ca on the physico-chemical properties of mixed micelles, that is, their zeta potential and size, as changes thereof could affect the uptake of micellarised LYC by intestinal cells. We indeed observed that adding Ca to the in vitro digestions significantly diminished the absolute value of the zeta potential of the mixed micelles. We suggest that Ca cations bind to the negatively charged micelles and consequently diminish their electrical charge. This effect was maximal when 10-mg Ca was added, suggesting that only a limited number of the negative charges of the micelles was available for the Ca cations. The Ca-induced modification of micelle electrical charge could in turn affect LYC uptake by enterocytes as it has been shown that the apex region of the membrane protein involved in LYC uptake, that is SR-BI⁽¹⁸⁾, exhibits a significant accumulation of cationic residues and that electrostatic interaction contributes to the binding of SR-BI to its ligands, impacting micelle interactions with the surface receptor loop⁽³⁷⁾. Obviously, other mechanisms can be involved in the observed effect of Ca on LYC bioavailability. For example, we can suggest an effect on SR-BI expression, as SR-BI expression has been shown to be significantly diminished in the presence of Ca in human keratinocytes⁽³⁸⁾. Nevertheless, other studies are required to verify this hypothesis.

In conclusion, this study shows for the first time that a dietary dose of Ca, that is, half the RDA for a male adult, ingested together with a food source of LYC, that is, tomato paste, can significantly impair LYC bioavailability. It also suggests that this is due, at least partly, to an effect of Ca ions on mixed micelle zeta potential. The pathophysiological consequences of this interaction are not known, but these results suggest that the long-term consumption of high doses of Ca, such as those found in dairy products or in some mineral waters, can diminish body LYC status. As LYC status has been inversely related to prostate cancer and CVD risk, we hypothesise that the positive association between Ca intake and incidence rate of these diseases is due, at least in part, to the negative effect of Ca on LYC bioavailability. Obviously, further experiments are required to verify the validity of this hypothesis. Finally, these results call for a thorough assessment of the effects of Ca, or other divalent minerals, on the bioavailability of other carotenoids and lipophilic micronutrients.

Acknowledgements

The authors are very grateful to the physician and nurses of the Human Nutrition Research Centre of Auvergne and to Patrice Reiling for their technical assistance.

The present study has received research funding from the European Community's seventh Framework Programme (FP7 2007–2013). The funding was attributed to the Dream project (grant agreement no. FP7-222654-2), which was an integrated project within the framework of the 'Food Quality and Safety' programme. This publication reflects only the view of the authors. The Dream community is not liable for any use that may be made of the results.

P. B., J. L. S. and D. R. designed the study; C. Buisson and C. Buffière conducted the clinical study; D. P. analysed tomato

paste lycopene; U. D. and C. D. performed the *in vitro* studies; C. H. analysed plasma lycopene; P. B. drafted the paper; P. B. and C. D. analysed the results and had primary responsibility for final content of the manuscript.

The authors declare that there are no conflicts of interest.

References

- Kristal AR & Cohen JH (2000) Invited commentary: tomatoes, lycopene, and prostate cancer. How strong is the evidence? *Am J Epidemiol* **151**, 124–127; discussion 128–130.
- Kucuk O, Sarkar FH, Djuric Z, *et al.* (2002) Effects of lycopene supplementation in patients with localized prostate cancer. *Exp Biol Med (Maywood)* 227, 881–885.
- Wertz K, Siler U & Goralczyk R (2004) Lycopene: modes of action to promote prostate health. *Arch Biochem Biophys* 430, 127–134.
- Jian L, Du CJ, Lee AH, *et al.* (2005) Do dietary lycopene and other carotenoids protect against prostate cancer? *Int J Cancer* 113, 1010–1014.
- 5. Graff RE, Pettersson A, Lis RT, *et al.* (2016) Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression. *Am J Clin Nutr* **103**, 851–860.
- Wang Y, Jacobs EJ, Newton CC, *et al.* (2016) Lycopene, tomato products and prostate cancer-specific mortality among men diagnosed with nonmetastatic prostate cancer in the Cancer Prevention Study II Nutrition Cohort. *Int J Cancer* 138, 2846–2855.
- Müller L, Caris-Veyrat C, Lowe G, *et al.* (2015) Lycopene and its antioxidant role in the prevention of cardiovascular diseases – a critical review. *Crit Rev Food Sci Nutr* 56, 1868–1879.
- Böhm V (2012) Lycopene and heart health. *Mol Nutr Food Res* 56, 296–303.
- 9. Mordente A, Guantario B, Meucci E, *et al.* (2011) Lycopene and cardiovascular diseases: an update. *Curr Med Chem* **18**, 1146–1163.
- Moran NE, Cichon MJ, Riedl KM, *et al.* (2015) Compartmental and noncompartmental modeling of ¹³C-lycopene absorption, isomerization, and distribution kinetics in healthy adults. *Am J Clin Nutr* **102**, 1436–1449.
- 11. Cooperstone JL, Ralston RA, Riedl KM, *et al.* (2015) Enhanced bioavailability of lycopene when consumed as cis-isomers from tangerine compared to red tomato juice, a randomized, cross-over clinical trial. *Mol Nutr Food Res* **59**, 658–669.
- Borel P (2003) Factors affecting intestinal absorption of highly lipophilic food microconstituents (fat-soluble vitamins, carotenoids and phytosterols). *Clin Chem Lab Med* **41**, 979–994.
- Reboul E, Richelle M, Perrot E, *et al.* (2006) Bioaccessibility of carotenoids and vitamin E from their main dietary sources. *J Agric Food Chem* 54, 8749–8755.
- 14. Reboul E, Borel P, Mikail C, *et al.* (2005) Enrichment of tomato paste with 6% tomato peel increases lycopene and beta-carotene bioavailability in men. *J Nutr* **135**, 790–794.
- 15. Borel P, Desmarchelier C, Nowicki M, *et al.* (2015) Lycopene bioavailability is associated with a combination of genetic variants. *Free Radic Biol Med* **83**, 238–244.
- Tyssandier V, Reboul E, Dumas JF, *et al.* (2003) Processing of vegetable-born carotenoids in the human stomach and duodenum. *Am J Physiol Gastrointest Liver Physiol* 284, G913–G923.
- 17. Tyssandier V, Lyan B & Borel P (2001) Main factors governing the transfer of carotenoids from emulsion lipid droplets to micelles. *Biochim Biophys Acta* **1533**, 285–292.

- Moussa M, Landrier JF, Reboul E, *et al.* (2008) Lycopene absorption in human intestinal cells and in mice involves scavenger receptor class B type I but not Niemann-Pick C1-like 1. *J Nutr* **138**, 1432–1436.
- Moussa M, Gouranton E, Gleize B, *et al.* (2011) CD36 is involved in lycopene and lutein uptake by adipocytes and adipose tissue cultures. *Mol Nutr Food Res* 55, 578–584.
- Reboul E & Borel P (2011) Proteins involved in uptake, intracellular transport and basolateral secretion of fat-soluble vitamins and carotenoids by mammalian enterocytes. *Prog Lipid Res* **50**, 388–402.
- Tyssandier V, Cardinault N, Caris-Veyrat C, *et al.* (2002) Vegetable-borne lutein, lycopene, and beta-carotene compete for incorporation into chylomicrons, with no adverse effect on the medium-term (3-wk) plasma status of carotenoids in humans. *Am J Clin Nutr* **75**, 526–534.
- 22. Gleize B, Tourniaire F, Depezay L, *et al.* (2013) Effect of type of TAG fatty acids on lutein and zeaxanthin bioavailability. *Br J Nutr* **110**, 1–10.
- Chappell JE, Clandinin MT, Kearney-Volpe C, *et al.* (1986) Fatty acid balance studies in premature infants fed human milk or formula: effect of calcium supplementation. *J Pediatr* 108, 439–447.
- 24. Corte-Real J, Iddir M, Soukoulis C, *et al.* (2016) Effect of divalent minerals on the bioaccessibility of pure carotenoids and on physical properties of gastro-intestinal fluids. *Food Chem* **197**, 546–553.
- 25. Cardinault N, Tyssandier V, Grolier P, *et al.* (2003) Comparison of the postprandial chylomicron carotenoid responses in young and older subjects. *Eur J Nutr* **42**, 315–323.
- Richelle M, Lambelet P, Rytz A, *et al.* (2012) The proportion of lycopene isomers in human plasma is modulated by lycopene isomer profile in the meal but not by lycopene preparation. *Br J Nutr* **107**, 1482–1488.
- Food and Nutrition Board (2011) Dietary Reference Intakes (DRIs): Recommended Dietary Allowances and Adequate Intakes, Vitamins. Washington, DC: Food and Nutrition Board, Institute of Medicine, National Academy.
- Page D, Van Stratum E, Degrou A, et al. (2012) Kinetics of temperature increase during tomato processing

modulate the bioaccessibility of lycopene. Food Chem 135, 2462–2469.

- Gleize B, Steib M, Andre M, *et al.* (2012) Simple and fast HPLC method for simultaneous determination of retinol, tocopherols, coenzyme Q10 and carotenoids in complex samples. *Food Chem* 134, 2560–2564.
- 30. Borel P, Moussa M, Reboul E, *et al.* (2009) Human fasting plasma concentrations of vitamin E and carotenoids, and their association with genetic variants in apo C-III, cholesteryl ester transfer protein, hepatic lipase, intestinal fatty acid binding protein and microsomal triacylglycerol transfer protein. *Br J Nutr* **101**, 680–687.
- Borel P, Moussa M, Reboul E, *et al.* (2007) Human plasma levels of vitamin E and carotenoids are associated with genetic polymorphisms in genes involved in lipid metabolism. *J Nutr* 137, 2653–2659.
- 32. Graff RE, Pettersson A, Lis RT, *et al.* (2016) Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression. *Am J Clin Nutr* **103**, 851–860.
- 33. Aune D, Navarro Rosenblatt DA, Chan DS, *et al.* (2015) Dairy products, calcium, and prostate cancer risk: a systematic review and meta-analysis of cohort studies. *Am J Clin Nutr* **101**, 87–117.
- Butler LM, Wong AS, Koh WP, *et al.* (2010) Calcium intake increases risk of prostate cancer among Singapore Chinese. *Cancer Res* 70, 4941–4948.
- 35. Wilson KM, Shui IM, Mucci LA, *et al.* (2015) Calcium and phosphorus intake and prostate cancer risk: a 24-y follow-up study. *Am J Clin Nutr* **101**, 173–183.
- Biehler E, Hoffmann L, Krause E, *et al.* (2011) Divalent minerals decrease micellarization and uptake of carotenoids and digestion products into Caco-2 cells. *J Nutr* 141, 1769–1776.
- Goncalves A, Gontero B, Nowicki M, et al. (2015) Micellar lipid composition affects micelle interaction with class B scavenger receptor extracellular loops. J Lipid Res 56, 1123–1133.
- Tsuruoka H, Khovidhunkit W, Brown BE, *et al.* (2002) Scavenger receptor class B type I is expressed in cultured keratinocytes and epidermis. Regulation in response to changes in cholesterol homeostasis and barrier requirements. *J Biol Chem* 277, 2916–2922.

6